Tango Therapeutics, Inc. (TNGX): Price and Financial Metrics

Tango Therapeutics, Inc. (TNGX): $7.45

0.14 (-1.84%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add TNGX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#344 of 361

in industry

TNGX Price/Volume Stats

Current price $7.45 52-week high $13.03
Prev. close $7.59 52-week low $2.47
Day low $7.43 Volume 196,389
Day high $7.80 Avg. volume 670,697
50-day MA $10.04 Dividend yield N/A
200-day MA $8.35 Market Cap 795.05M

TNGX Stock Price Chart Interactive Chart >


Tango Therapeutics, Inc. (TNGX) Company Bio


Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.


TNGX Latest News Stream


Event/Time News Detail
Loading, please wait...

TNGX Latest Social Stream


Loading social stream, please wait...

View Full TNGX Social Stream

Latest TNGX News From Around the Web

Below are the latest news stories about TANGO THERAPEUTICS INC that investors may wish to consider to help them evaluate TNGX as an investment opportunity.

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers – BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology (SNO) 28th Annual Meeting taking plac

Yahoo | November 13, 2023

Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business Updates

Advancing Precision Oncology: Tango Therapeutics Highlights Clinical Progress and Financial Health

Yahoo | November 8, 2023

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nexte

Yahoo | November 8, 2023

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 1:00 PM GMT. A live webcast of the presentation will be available under the "Even

Yahoo | November 7, 2023

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts. Abstracts accepted for poster presentation Title:

Yahoo | September 18, 2023

Read More 'TNGX' Stories Here

TNGX Price Returns

1-mo -19.20%
3-mo -31.90%
6-mo -3.12%
1-year 65.92%
3-year -33.54%
5-year N/A
YTD -24.75%
2023 36.55%
2022 -33.73%
2021 -4.37%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!